The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
Epistemonikos ID: f2ffd8bd25c63aeba35b8f80ed396d2a8d144649
First added on: May 15, 2024